Drug
Omaveloxolone
Omaveloxolone: highest development phase Phase 3, developed by Biogen. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Omaveloxolone NCT06953583 | Phase 3 | Friedreich Ataxia |
| Omaveloxolone Capsules, 2.5 mg NCT02255435 | Phase 2 | Friedreich Ataxia |
| Omaveloxolone Capsules (2.5 mg/capsule) NCT02259231 | Phase 1/2 | Melanoma |
| Omaveloxolone NCT05909644 | Phase 1 | Healthy Adult Subjects |
Latest
No recent events.
Follow Omaveloxolone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.